India emerging as a key player in the global pharmaceutical supply chain
News: India’s Contract Research, Development, and Manufacturing Organization (CRDMO) industry is set to double from USD 7 billion to USD 14 billion by 2028, growing at a 14% CAGR, according to a Macquarie Equity Research report.
Regulatory support, rising pharmaceutical outsourcing, and global supply chain shifts are driving this growth. The US Biosecure Act could further accelerate expansion, potentially pushing the market to USD 22 billion by 2030.
India’s cost advantage (30-40% lower than Western counterparts), strong regulatory approvals (USFDA, EMA), and expertise in APIs and speciality chemicals make it a preferred destination for pharmaceutical outsourcing. As global firms reduce reliance on China, India is emerging as a key player in the pharmaceutical supply chain.
Source: The Economic Times
Join The Community
Recent News
-
Trump’s Tariffs Complicate Costly Questions Over China Supply -
BCAS Eases Cargo Re-Screening Rules, Boosting Speed of Air Freight Operations -
India-UK Trade Pact Sealed: 99% of Indian Exports to Enter UK Duty-Free -
Trump Warns India May Face 25% Tariffs -
Green Warehousing on the Rise in India as Global Firms Push for Sustainability
1 Comment